Efficacy of Anidulafungin in 105 Patients with Deep Tissue Candidiasis

Ref ID: 18791

Author:

U. Conte, PharmD – Clinician1, H. Schlamm, MD – Medical Development Lead 1, P. Biswas, PhD – Statistician 1, B. Kullberg, MD, PhD – Professor of Medicine 2, M. Ruhnke, MD – Professor of Medicine 3;

Author address:

1Pfizer Inc., New York, NY, 2Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 3Charité Univ.smedizin, Berlin, Germany.

Full conference title:

52nd Annual ICAAC

Date: 9 September 2014

Abstract:

Background: Deep tissue candidiasis remains a difficult to treat infection and is associated with substantial mortality. The recent completion of 4 similar prospective, open-label, non-comparative studies conducted in the USA, Canada, Latin America, Europe and Asia allowed us to create a large database of patients with IC treated with anidulafungin and enabled us to assess efficacy in a substantial number of patients with deep tissue candidiasis. Methods: Data from patients with microbiologically-confirmed deep tissue candidiasis enrolled in these 4 regional studies were pooled into a database. Each patient was initially treated with IV anidulafungin with an option to step down to an oral azole. Total treatment duration was ≥ 14 days. The primary endpoint was global response (based on investigator-assessed clinical and microbiological response) at the end of therapy (EOT). Results: 105 subjects (mean age 61.2 yrs) were included in the analysis. Mean APACHE II score was 15.2. Sites of infection included intraabdominal (83.8%), kidney (2.9%), bone (3.8%), pleural space (6.7%), and other (6.7%). Baseline Candida spp. included C albicans (63.8%), C glabrata (31.4%), C tropicalis (11.4%), C krusei (5.7%), C parapsilosis (0.9%), C kefyr (0.9%), and unknown Candida sp. (1.9%). Mean duration of treatment with anidulafungin was 13.3 d; step down to an oral azole occurred in 46 (43.8%) patients; mean duration of all antifungal therapy was 18.1 d. Rate of successful global response at EOT was 70.5%. All-cause mortality at 14 and 28 d post-treatment was 18.1% (19/105) and 22.9% (24/105), respectively. Conclusion: In this relatively large group of patients with deep tissue candidiasis treated with anidulafungin, the rate of successful global response at EOT was consistent with response rates observed in published studies, with relatively low mortality.

Abstract Number: M-1709

Conference Poster: y

Conference Year: 2012

Link to conference website: NULL

New link: NULL

Conference abstracts, posters & presentations

Showing 10 posts of 17325 posts found.

  • Title

    Author

    Year

    Number

    Poster